What is HC Wainwright’s Forecast for Alumis FY2024 Earnings?

Alumis Inc. (NASDAQ:ALMS) – Research analysts at HC Wainwright upped their FY2024 earnings per share (EPS) estimates for shares of Alumis in a report released on Thursday, November 14th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings of ($9.75) per share for the year, up from their previous estimate of ($11.42). HC Wainwright has a “Buy” rating and a $26.00 price objective on the stock. The consensus estimate for Alumis’ current full-year earnings is ($7.98) per share. HC Wainwright also issued estimates for Alumis’ Q4 2024 earnings at ($1.39) EPS, Q1 2025 earnings at ($1.40) EPS, Q2 2025 earnings at ($1.41) EPS, Q3 2025 earnings at ($1.43) EPS, Q4 2025 earnings at ($1.45) EPS and FY2025 earnings at ($5.68) EPS.

A number of other research firms also recently commented on ALMS. Cantor Fitzgerald reissued an “overweight” rating on shares of Alumis in a report on Thursday, November 14th. Guggenheim started coverage on shares of Alumis in a report on Tuesday, July 23rd. They set a “buy” rating and a $32.00 price objective on the stock. Leerink Partners initiated coverage on shares of Alumis in a report on Tuesday, July 23rd. They issued an “outperform” rating and a $29.00 target price for the company. Baird R W raised Alumis to a “strong-buy” rating in a research note on Thursday, October 31st. Finally, Morgan Stanley initiated coverage on Alumis in a research note on Tuesday, July 23rd. They issued an “overweight” rating and a $36.00 price objective for the company. Six analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $26.83.

Alumis Trading Down 2.4 %

Alumis stock opened at $8.64 on Monday. The company has a 50 day simple moving average of $11.22. Alumis has a 1-year low of $8.23 and a 1-year high of $13.53.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC acquired a new stake in Alumis during the 3rd quarter valued at $3,266,000. Barclays PLC acquired a new stake in shares of Alumis during the third quarter valued at $197,000. State Street Corp purchased a new stake in Alumis during the 3rd quarter worth about $866,000. Stifel Financial Corp acquired a new position in Alumis in the 3rd quarter valued at about $931,000. Finally, Samsara BioCapital LLC purchased a new position in Alumis in the 3rd quarter valued at about $34,886,000.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.